Bio News
U.S.-based Infixion Biosciences received the top award at the 2026 Bio International Convention Startup Stadium for its development of a treatment for neurofibromatosis type 1 (NF1).
Infixion increased protein production from the normal NF1 gene by up to 80% using an antisense oligonucleotide (ASO).
Infixion plans to optimize safety and efficacy in human NF1 organoids and animal models.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
